Icon

STEGLATRO (nda209803)- (5MG,15MG)

ERTUGLIFLOZIN MSD SUB MERCK
5MG,15MG
Yes No
2030-Jul-13 2022-Dec-19
None None
None No
STEGLATRO is a sodium glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
2 1 0
Total Other Developers 8
Drugs with Suitability No
5MG ** ** Up - -
15MG ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.